lapatinib has been researched along with Chronic Hepatitis C in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alem, F; Bhalla, N; Boghdeh, NA; Brown, JA; Chiem, K; Chiu, W; Cohen, CA; Das, S; De Jonghe, S; Durán, V; Dye, JM; Einav, S; Ghita, L; Ghosh, P; Huang, PT; Huie, KE; Jin, J; Jochmans, D; Karim, M; Khalil, AM; Kumar, S; Leyssen, P; Lo, CW; Martinez-Sobrido, L; Narayanan, A; Neyts, J; Pinsky, BA; Saul, S; Sibai, M; Solow-Cordero, DE; Tindle, C; Tran, DH; Wikswo, JP; Ye, C | 1 |
| Kassem, H; Kassem, N; Talima, S | 1 |
2 other study(ies) available for lapatinib and Chronic Hepatitis C
| Article | Year |
|---|---|
Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects.
Topics: Animals; Antiviral Agents; COVID-19; Cytokines; Hepatitis C, Chronic; Humans; Inflammation; Lapatinib; Mice; SARS-CoV-2 | 2023 |
Chemotherapy and targeted therapy for breast cancer patients with hepatitis C virus infection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Breast Neoplasms; Breast Neoplasms, Male; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lapatinib; Liver; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Trastuzumab; Virus Replication | 2019 |